SCHEMBL5477278

SCHEMBL5477278

CN1CCN(C(=O)NCc2c(Cl)cccc2Cl)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.58
MEN1 O00255 3/20 0.58
P2RX7 Q99572 2/20 0.48
HRH3 Q9Y5N1 1/20 0.47
KDM4E B2RXH2 3/20 0.47
MAPK8 P45983 1/20 0.47
LMNA P02545 2/20 0.46
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HTR2C P28335 1/20 0.45
PKM P14618 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459563 0.92 ALDH1A1 (0.55) KMT2AMEN1P2RX7KDM4ELMNA
SCHEMBL5472065 0.87 LMNA (0.60) KMT2AMEN1HRH3KDM4EMAPK8
SCHEMBL5464308 0.86 MEN1 (0.53) KMT2AMEN1P2RX7MAPK8PKM
SCHEMBL5468451 0.85 MEN1 (0.56) KMT2AMEN1P2RX7MAPK8ALDH1A1
SCHEMBL5462647 0.85 MEN1 (0.62) KMT2AMEN1P2RX7KDM4EMAPK8
SCHEMBL25196992 0.82 P2RX7 (0.48) KMT2AMEN1P2RX7HRH3LMNA
SCHEMBL25218628 0.81 NPSR1 (0.51) KMT2AMEN1P2RX7HRH3ALDH1A1
SCHEMBL5472340 0.80 KMT2A (0.60) KMT2AMEN1HRH3KDM4EMAPK8
SCHEMBL5462660 0.79 P2RX7 (0.54) KMT2AMEN1P2RX7MAPK8HTR2C
SCHEMBL5466273 0.79 KMT2A (0.76) KMT2AMEN1HRH3KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression HRH3, HRH1, HRH4 KMT2A 323/4885MEN1 3623/4885P2RX7 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.